Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib

Oncologist

Volumn 13, Issue 9, 2008, Pages 1001-1011

  Lacouture, Mario E ^a   Wu, Shenhong ^b   Robert, Caroline ^c   Atkins, Michael B ^d   Kong, Heidi H ^e   Guitart, Joan ^a   Garbe, Claus ^f   Hauschild, Axel ^g   Puzanov, Igor ^h   Alexandrescu, Doru T ⁱ   Anderson, Roger T ^j   Wood, Laura ^k   Dutcher, Janice P ^l  

^a NORTHWESTERN UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

^h VANDERBILT INGRAM CANCER CENTER   (United States)

ⁱ Georgetown Dermatology   (United States)

^j PENN STATE COLLEGE OF MEDICINE   (United States)

^k TAUSSIG CANCER INSTITUTE   (United States)

^l NEW YORK MEDICAL COLLEGE   (United States)

more..

Author keywords

Forum consensus; Hand foot skin reaction; Skin; Sorafenib; Sunitinib

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CYTARABINE; FLUOROURACIL; IMATINIB; KERATOLYTIC AGENT; LIDOCAINE; PHOSPHOTRANSFERASE INHIBITOR; SORAFENIB; SUNITINIB; TAZAROTENE; UREA;

ALOPECIA; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; ERYTHEMA; FATIGUE; GASTROINTESTINAL TUMOR; HAND AND FOOT SKIN REACTION; HAND FOOT SKIN REACTION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RASH; SKIN DISCOLORATION; SKIN DISEASE; SKIN MANIFESTATION; STOMATITIS; SUBUNGUAL SPLINTER HEMORRHAGE;

BENZENESULFONATES; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; INDOLES; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; QUALITY OF LIFE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 52949128348     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0131     Document Type: Conference Paper

References (57)

1. Chu D, Lacouture ME, Fillos T et al. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol 2008;47:176-186.
2. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
3. Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: Novel targeted therapies for renal cell cancer. Pharmacotherapy 2007;27:1125-1144.
4. Bracarda S, Caserta C, Sordini L et al. Protein kinase inhibitors in the treatment of renal cell carcinoma: Sorafenib. Ann Oncol 2007;18(suppl 6):vi22-vi25.
5. Wood LS, Manchen B. Sorafenib: A promising new targeted therapy for renal cell carcinoma. Clin J Oncol Nurs 2007;11:649-656.
6. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
7. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-1338.
8. Nexavar [package insert]. West Haven, CT: Bayer Pharmaceuticals Corporation, 2007.
9. Sutent [package insert]. New York: Pfizer Labs, 2007.
10. Azad NS, Annunzuata C, Barrett T et al. Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: Clinical and translational results. J Clin Oncol 2007;25(18 suppl):3542.
11. Thompson DS, Greco FA, Spigel DR et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial. J Clin Oncol 2006;24(18 suppl):4594.
12. Beldner M, Jacobson M, Burges GE et al. Localized palmar-plantar epidermal hyperplasia: A previously undefined dermatologic toxicity to sorafenib. The Oncologist 2007;12:1178-1182.
13. Porta C, Paglino C, Imarisio I et al. Uncovering Pandora's vase: The growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007;7:127-134.
14. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
15. Schenone S, Bondavalli F, Botta M. Antiangiogenic agents: An update on small molecule VEGFR inhibitors. Curr Med Chem 2007;14:2495-2516.
16. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-286.
17. Erber R, Thurnher A, Katsen AD et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-340.
18. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
19. Lammie A, Drobnjak M, Gerald W et al. Expression of c-Kit and Kit ligand proteins in normal human tissues. J Histochem Cytochem 1994;42:1417-1425.
20. Moss KG, Toner GC, Cherrington JM et al. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 2003;307:476-480.
21. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-11858.
22. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
23. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
24. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed March 20, 2008.
25. Escudier B, Lassau N, Angevin E et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007;13:1801-1809.
26. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
27. Bhojani N, Jeldres C, Patard JJ et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-930.
28. Grn̈wald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 2007;30:519-524.
29. Rosenbaum SE, Wu S, Newman MA et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008;16:557-566.
30. Dasanu CA, Alexandrescu DT, Dutcher J. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J 2007;100:328-330.
31. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10:6388S-6392S.
32. Lacouture ME, Desai A, Soltani K et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 2006;31:783-785.
33. Chu D, Lacouture ME, Weiner E et al. Risk of hand-foot skin reaction with a multitargeted kinase inhibitor sunitinib in patients with renal cell and nonrenal cell carcinoma. Clin Genitourin Cancer 2008 (in press).
34. Sheen YS, Huang CL, Chu CY. Eccrine squamous syringometaplasia associated with sunitinib therapy. J Eur Acad Dermatol Venereol 2007;21:1136-1137.
35. Yang CH, Lin WC, Chuang CK et al. Hand-foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158:592-596.
36. Lacouture ME, Reilly LM, Gerami P et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008 [Epub ahead of print]. doi:10.1093/annonc/mdn389.
37. Do JE, Kim YC. Capecitabine-induced diffuse palmoplantar keratoderma: Is it a sequential event of hand-foot syndrome? Clin Exp Dermatol 2007;32:519-521.
38. Gordon KB, Tajuddin A, Guitart J et al. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995;75:2169-2173.
39. Suwattee P, Chow S, Berg BC et al. Sunitinib: A cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol 2008;144:123-125.
40. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000;1:225-234.
41. Jacobi U, Waibler E, Schulze P et al. Release of doxorubicin in sweat: First step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 2005;16:1210-1211.
42. Ansel JC, Tiesman JP, Olerud JE et al. Human keratinocytes are a major source of cutaneous platelet-derived growth factor. J Clin Invest 1993;92:671-678.
43. Ponten F, Ren Z, Nister M et al. Epithelial-stromal interactions in basal cell cancer: The PDGF system. J Invest Dermatol 1994;102:304-309.
44. Katz S, Akpom CA. 12. Index of ADL. Med Care 1976;14(5 suppl):116-118.
45. Spector WD, Katz S, Murphy JB et al. The hierarchical relationship between activities of daily living and instrumental activities of daily living. J Chronic Dis 1987;40:481-489.
46. Avlund K, Schultz-Larsen K, Kreiner S. The measurement of instrumental ADL: Content validity and construct validity. Aging (Milano) 1993;5:371-383.
47. National Cancer Institute. Dictionary of Cancer Terms. Available at http://www.cancer.gov/templates/db_alpha.aspx?expand=A. Accessed April 23, 2008.
48. Duvic M, Asano AT, Hager C et al. The pathogenesis of psoriasis and the mechanism of action of tazarotene. J Am Acad Dermatol 1998;39:S129-S133.
49. Hagemann I, Proksch E. Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm Venereol 1996;76:353-356.
50. Yancovitz M, Pasternack FR, Ward KM et al. Keratosis punctata palmaris et plantaris treated with topical fluorouracil. Arch Dermatol 2006;142:1074-1076.
51. Osman Y, Daly TJ, Don PC. Spiny keratoderma of the palms and soles. J Am Acad Dermatol 1992;26:879-881.
52. Breccia M, Carmosino I, Russo E et al. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 2005;74:121-123.
53. Graham S, Dutcher J, Rosal-Greif V et al. Incidence and nursing management of hand foot skin reaction in patients treated with oral tyrosine kinase inhibitors for metastatic renal cell carcinoma. Presented at the Oncology Nursing Society 32nd Annual Congress 2007, Las Vegas, NV, April 24-27, 2007.
54. de Korte J, Sprangers MAG, Mombers FMC et al. Quality of life in patients with psoriasis: A systematic literature review. J Investig Dermatol Symp Proc 2004;9:140-147.
55. Huggins RH, Kuzel TM, Anderson RT et al. Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: Impact on quality of life (QoL). J Clin Oncol 2008;26(May 20 suppl):Abstract 16122.
56. Chren MM, Lasek RJ, Quinn LM et al. Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life in patients with skin disease. J Invest Dermatol 1997;108:103-107.
57. Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol 1997;37:41-50.